Last reviewed · How we verify

NCT06207851

Transcatheter Arterial Micro-Embolization (TAME) Using Nexsphere-F in Patients With Chronic Pain in Elbow or Wrist

Recruiting now NA Last updated 25 March 2024
What this trial tests

NA trial testing Transcatheter Arterial Micro-Embolization in Osteoarthritis in 38 participants. Currently enrolling.

Timeline
13 July 2023
Primary endpoint
13 July 2026
13 July 2026

Quick facts

Lead sponsorNext Biomedical Co., Ltd.
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment38
Start date13 July 2023
Primary completion13 July 2026
Estimated completion13 July 2026
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Next Biomedical Co., Ltd. — full company profile →

Who can join

Adults 19 to 80, any sex, with Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In patients with chronic elbow or wrist pain, the pain is controlled by conventional conservative therapy The pain reduction effect of Nexsphere-F embolization in patients who need additional treatment It is intended to demonstrate safety.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Osteoarthritis

Currently open trials in the same condition.

Other Next Biomedical Co., Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06207851.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing